{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:04:49Z","timestamp":1793387089646,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T00:00:00Z","timestamp":1572393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Au1"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>HAART had significantly improved the quality of life of HIV patients. However, it results different adverse effects such as: hepatotoxicity, nephrotoxicity, lipodystrophy, anemia, diarrhea, psychiatric disorder and others. Therefore, this comparative cross sectional study was designed to investigate liver enzyme elevation in patients taking HAART compared with treatment na\u00efve controls at Debre Berhan Referral Hospital.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Result<\/jats:title>\n                <jats:p>A total of 152 individuals (76 cases and 76 controls) were included in this study. The mean ages of treatment and control groups were 37.37 and 36.38 respectively. The mean values of liver enzymes (ALT, AST and ALP), total bilirubin and direct bilirubin were significantly higher (p\u2009&lt;\u20090.05) while, total protein and creatinine were significantly lower in patients taking HAART compared with treatment na\u00efve controls. In this study, about 19 (25%) of clients in HAART treated groups and 7 (9.2%) of treatment na\u00efve controls had showed liver enzyme changes. Moreover, 23.7% and 1.3% of the HAART treated groups developed mild and moderate liver enzyme elevation or hepatotoxicity, respectively. In this study, significant difference was observed in liver enzyme elevation between ART and pre-ART patients. As a result, regular clinical and laboratory monitoring of liver function will be necessary to prevent severe form of liver injury.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-019-4748-4","type":"journal-article","created":{"date-parts":[[2019,10,30]],"date-time":"2019-10-30T23:03:14Z","timestamp":1572476594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Liver enzyme elevation in patients taking HAART compared with treatment na\u00efve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-2190","authenticated-orcid":false,"given":"Endalamaw","family":"Tesfa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Siefu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yididya","family":"Belayneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewdie","family":"Mekonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,30]]},"reference":[{"key":"4748_CR1","doi-asserted-by":"publisher","DOI":"10.5530\/ijopp.7.3.7","author":"K Khan","year":"2014","unstructured":"Khan K, Khan A, Sulaiman S, Soo C, Aftab R. Adverse effect of highly active anti-retroviral therapy (HAART) in HIV\/AIDS patients. Indian J Pharm Pract. 2014. \n                    https:\/\/doi.org\/10.5530\/ijopp.7.3.7\n                    \n                  .","journal-title":"Indian J Pharm Pract"},{"key":"4748_CR2","unstructured":"Federal HIV\/AIDS Prevention and Control Office and Federal Ministry of Health (FHAPCO). Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia. 2008. p. 77\u201380: \n                    http:\/\/www.who.int\/hiv\/pub\/guidelines\/ethiopia_art\n                    \n                  ."},{"key":"4748_CR3","doi-asserted-by":"publisher","DOI":"10.1086\/381499","author":"S Pol","year":"2004","unstructured":"Pol S, Lebray P, Pichard A. HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms. Clin Infect Dis. 2004. \n                    https:\/\/doi.org\/10.1086\/381499\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4748_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jhep.2002.30319","volume":"35","author":"M Sulkowski","year":"2002","unstructured":"Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182\u20139. \n                    https:\/\/doi.org\/10.1053\/jhep.2002.30319\n                    \n                  .","journal-title":"Hepatology"},{"key":"4748_CR5","volume-title":"Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]","author":"K Shepard","year":"2004","unstructured":"Shepard K. Clarification of risk factors for severe, life threatening and fatal hepatotoxicity with Viramune (nevirapine) [letter]. Rigdefield: Boehringer Ingelheim Pharmaceuticals; 2004."},{"key":"4748_CR6","doi-asserted-by":"publisher","DOI":"10.1086\/428093","author":"I Sanne","year":"2005","unstructured":"Sanne I, Mommeja-Marin H, Hinkle J, Bartlett A, Lederman M, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005. \n                    https:\/\/doi.org\/10.1086\/428093\n                    \n                  .","journal-title":"J Infect Dis"},{"issue":"11","key":"4748_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1258\/09564620360719840","volume":"14","author":"J Ena","year":"2003","unstructured":"Ena J, Amador C, Benito C, Fenoll V, Pasquau F. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. Int J STD AIDS. 2003;14(11):776\u201381. \n                    https:\/\/doi.org\/10.1258\/09564620360719840\n                    \n                  .","journal-title":"Int J STD AIDS"},{"issue":"7","key":"4748_CR8","first-page":"343","volume":"13","author":"S Br\u00fcck","year":"2008","unstructured":"Br\u00fcck S, Witte S, Brust J, Schuster D, Mosthaf F, Procaccianti M, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res. 2008;13(7):343\u20138.","journal-title":"Eur J Med Res."},{"key":"4748_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-105","author":"T Mbougua","year":"2010","unstructured":"Mbougua T, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, et al. Hepatotoxicity and effectiveness of a nevirapine based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health. 2010. \n                    https:\/\/doi.org\/10.1186\/1471-2458-10-105\n                    \n                  .","journal-title":"BMC Public Health."},{"key":"4748_CR10","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i3.329","author":"R Andrade","year":"2007","unstructured":"Andrade R, Robles M, Fern\u00e1ndez-Casta\u00f1er A, L\u00f3pez-Ortega S, L\u00f3pez-Vega M, Lucena M. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol. 2007. \n                    https:\/\/doi.org\/10.3748\/wjg.v13.i3.329\n                    \n                  .","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4748_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","volume":"22","author":"V Soriano","year":"2008","unstructured":"Soriano V, Puoti M, Garcia-Gasco P, Rockstrohc J, Benhamoud Y, Barreiroa P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1\u201313. \n                    https:\/\/doi.org\/10.1097\/QAD.0b013e3282f0e2fd\n                    \n                  .","journal-title":"AIDS."},{"issue":"8","key":"4748_CR12","doi-asserted-by":"publisher","first-page":"e0134449","DOI":"10.1371\/journal.pone.0134449","volume":"10","author":"D Nii","year":"2015","unstructured":"Nii D, Osakunor M, Obirikorang C, Fianu V, Asare I, Dakorah M. Hepatic enzyme alterations in HIV patients on antiretroviral therapy: a case-control study in a hospital setting in Ghana. PLoS ONE. 2015;10(8):e0134449. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0134449\n                    \n                  .","journal-title":"PLoS ONE"},{"key":"4748_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1985452","author":"M Shiferaw","year":"2016","unstructured":"Shiferaw M, Tulu K, Zegeye A, Wubante A. Liver enzymes abnormalities among highly active antiretroviral therapy experienced and HAART na\u00efve HIV-1 infected patients at Debre Tabor Hospital, North West Ethiopia: a comparative cross-sectional study. AIDS Res Treat. 2016. \n                    https:\/\/doi.org\/10.1155\/2016\/1985452\n                    \n                  .","journal-title":"AIDS Res Treat"},{"issue":"3","key":"4748_CR14","first-page":"048","volume":"2","author":"C Fokunang","year":"2010","unstructured":"Fokunang C, Banin A, Kouanfack C, Ngogang J. Evaluation of hepatotoxicity and nephrotoxicity in HIV patients on highly active anti-retroviral therapy. J AIDS HIV Res. 2010;2(3):048\u201357.","journal-title":"J AIDS HIV Res"},{"issue":"7","key":"4748_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","volume":"24","author":"N Kaplowitz","year":"2001","unstructured":"Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24(7):483\u201390.","journal-title":"Drug Saf"},{"issue":"8","key":"4748_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17354\/ijss\/2015\/499","volume":"3","author":"M Savita","year":"2015","unstructured":"Savita M, Singh B, Vengadakrishnan K, Damodharan J. Liver function abnormalities in human immunodeficiency virus positive individuals and its correlation with disease severity. Int J Sci Study. 2015;3(8):15\u20138. \n                    https:\/\/doi.org\/10.17354\/ijss\/2015\/499\n                    \n                  .","journal-title":"Int J Sci Study"},{"key":"4748_CR17","unstructured":"Ethiopian Central Statistics Agency (ECSA). Ethiopian Demographic and Health Survey report. 2011. p. 131. \n                    https:\/\/www.unicef.org\/ethiopia\/ET_2011_EDHS\n                    \n                  ."},{"key":"4748_CR18","unstructured":"Degu G, Tessema F. Lecture Notes for Health Science Students; University of Gondar In collaboration with the Ethiopia Public Health Training Initiative, The Carter Center, the Ethiopia Ministry of Health, and the Ethiopia Ministry of Education. 2005. p. 180\u20132. \n                    https:\/\/www.cartercenter.org\/\n                    \n                  ."},{"issue":"2","key":"4748_CR19","first-page":"107","volume":"50","author":"S Abdissa","year":"2012","unstructured":"Abdissa S, Fekade D, Feleke Y, Seboxa T, Diro E. Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital. Ethiop Med J. 2012;50(2):107\u201313.","journal-title":"Ethiop Med J"},{"issue":"9055","key":"4748_CR20","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349(9055):825\u201332.","journal-title":"Lancet"},{"issue":"6","key":"4748_CR21","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1517\/14740338.6.6.673","volume":"6","author":"SH Hussaini","year":"2007","unstructured":"Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury; an overview. Expert Opin Drug Saf. 2007;6(6):673\u201384. \n                    https:\/\/doi.org\/10.1517\/14740338.6.6.673\n                    \n                  .","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"4748_CR22","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1086\/593104","volume":"47","author":"CJ Hoffmann","year":"2008","unstructured":"Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47(11):1479\u201385. \n                    https:\/\/doi.org\/10.1086\/593104\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4748_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1089\/aid.2009.0211","volume":"26","author":"MK Baum","year":"2010","unstructured":"Baum MK, Rafie C, Lai S, Sales S, Page JB, Campa A. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26(5):511\u20138. \n                    https:\/\/doi.org\/10.1089\/aid.2009.0211\n                    \n                  .","journal-title":"AIDS Res Hum Retroviruses."},{"issue":"1","key":"4748_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.283.1.74","volume":"283","author":"M Sulkowski","year":"2000","unstructured":"Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74\u201380.","journal-title":"JAMA"},{"issue":"1\u20132","key":"4748_CR25","first-page":"49","volume":"7","author":"AU Rose","year":"2011","unstructured":"Rose AU, Abraham OM, Bode JB, Abel NO. Risk factors for hepatotoxicity after introduction of highly active antiretroviral therapy. E&C Hepatol. 2011;7(1\u20132):49\u201356.","journal-title":"E&C Hepatol"},{"key":"4748_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-5-58","author":"T Carlo","year":"2005","unstructured":"Carlo T, Giuseppe L, Salvatore C, Massimo P, Mark N, Eugenia Q, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients; results from the Italian EPOKA-Master Cohort. BMC Infect Dis. 2005. \n                    https:\/\/doi.org\/10.1186\/1471-2334-5-58\n                    \n                  .","journal-title":"BMC Infect Dis"},{"key":"4748_CR27","volume-title":"Tietz textbook of clinical chemistry and molecular diagnosis","author":"CA Burtis","year":"2006","unstructured":"Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnosis. 4th ed. Philadelphia: Elsevier Saunders Co; 2006.","edition":"4"},{"key":"4748_CR28","first-page":"1918","volume-title":"Harrison\u2019s principles of internal medicine","author":"G Marc","year":"2008","unstructured":"Marc G, Jay HH, Fauci S, Braunwald E, Kasper L, Hauser L, Longo L, Jameson L, Loscalzo J. Harrison\u2019s principles of internal medicine. 17th ed. New York: McGraw-Hill Companies; 2008. p. 1918\u20132000.","edition":"17"},{"issue":"10","key":"4748_CR29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1046\/j.1365-2036.2001.01086.x","volume":"15","author":"LV Hernandez","year":"2001","unstructured":"Hernandez LV, Gilson I, Jacobson J, Affi A, Puetz TR, Dindzans VJ. Antiretroviral hepatotoxicity in human immunodeficiency virus-infected patients. Aliment Pharmacol Ther. 2001;15(10):1627\u201332.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"4748_CR30","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1097\/qad.0b013e32814e6b08","volume":"21","author":"CJ Hoffmann","year":"2007","unstructured":"Hoffmann CJ, Charalambous S, Thio CL, Martin DJ, Pemb L, Fielding KL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21(10):1301\u20138. \n                    https:\/\/doi.org\/10.1097\/qad.0b013e32814e6b08\n                    \n                  .","journal-title":"AIDS."},{"issue":"9","key":"4748_CR31","first-page":"4275","volume":"4","author":"AA Emejulu","year":"2010","unstructured":"Emejulu AA, Ujowundu CO, Igwe CU, Ouwuliri VA. Hepatotoxicity of antiretroviral drugs in HIV seropositive Nigerian patients. Aust J Basic Appl Sci. 2010;4(9):4275\u20138.","journal-title":"Aust J Basic Appl Sci"},{"key":"4748_CR32","doi-asserted-by":"publisher","DOI":"10.1258\/ijsa.2009.009328","author":"KM Chu","year":"2012","unstructured":"Chu KM, Manzi M, Zuniga I, Biot M, Ford NP, Rasschaert F, et al. Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique. Int J STD AIDS. 2012. \n                    https:\/\/doi.org\/10.1258\/ijsa.2009.009328\n                    \n                  .","journal-title":"Int J STD AIDS."},{"key":"4748_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034x.2009.00608","author":"G Shicheng","year":"2010","unstructured":"Shicheng G, Xi-En G, Lipin D, Yongxi Z, Ke L, Rongrong Y, et al. Antiretroviral therapy hepatotoxicity: prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. Hepatol Res. 2010. \n                    https:\/\/doi.org\/10.1111\/j.1872-034x.2009.00608\n                    \n                  .","journal-title":"Hepatol Res"},{"issue":"4","key":"4748_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1086\/649922","volume":"50","author":"H Kovari","year":"2010","unstructured":"Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection. Clin Infect Dis. 2010;50(4):502\u201311. \n                    https:\/\/doi.org\/10.1086\/649922\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4748_CR35","first-page":"16","volume":"11","author":"R Kalyesubula","year":"2011","unstructured":"Kalyesubula R, Kagimu M, Opio C, Kiguba R, Semitala F, Schlech F, et al. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. Africa Health Sci. 2011;11(1):16\u201323.","journal-title":"Africa Health Sci"},{"issue":"5","key":"4748_CR36","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/00042560-200108150-00002","volume":"27","author":"M N\u00fa\u00f1ez","year":"2001","unstructured":"N\u00fa\u00f1ez M, Lana R, Mendoza L, Martin Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27(5):426\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"4748_CR37","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/tpj.2011.34","volume":"12","author":"G Yimer","year":"2012","unstructured":"Yimer G, Amogne W, Habtewold A, Makonnen E, Ueda N, Suda A, et al. High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naive HIV patients from Ethiopia; a prospective cohort study. Pharmacogenomics J. 2012;12(6):499\u2013506. \n                    https:\/\/doi.org\/10.1038\/tpj.2011.34\n                    \n                  .","journal-title":"Pharmacogenomics J"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13104-019-4748-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-019-4748-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:23:29Z","timestamp":1603931009000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-019-4748-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,30]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4748"],"URL":"https:\/\/doi.org\/10.1186\/s13104-019-4748-4","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,30]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical clearance was obtained from Addis Ababa University, College of Health Sciences ethical review committee. Permission was also requested and obtained from Debre Berhan Referral Hospital Manager through a letter written from Addis Ababa University, College of Health Sciences. We started the data collection after we obtained written informed consent from each study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"714"}}